Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension.

Bunclark K, Newnham M, Chiu YD, Ruggiero A, Villar SS, Cannon JE, Coghlan G, Corris PA, Howard L, Jenkins D, Johnson M, Kiely DG, Ng C, Screaton N, Sheares K, Taboada D, Tsui S, Wort SJ, Pepke-Zaba J, Toshner M.

J Thromb Haemost. 2019 Sep 26. doi: 10.1111/jth.14649. [Epub ahead of print]

PMID:
31557382
2.

Arrhythmic Burden and Outcomes in Pulmonary Arterial Hypertension.

Middleton JT, Maulik A, Lewis R, Kiely DG, Toshner M, Charalampopoulos A, Kyriacou A, Rothman A.

Front Med (Lausanne). 2019 Jul 23;6:169. doi: 10.3389/fmed.2019.00169. eCollection 2019. Review.

3.

Chronic thromboembolic pulmonary hypertension following long-term peripherally inserted central venous catheter use.

Masding A, Preston SD, Toshner M, Barnett J, Harries C, Dimopoulos K, Kempny A, McCabe C, Jenkins DP, Wort SJ, Price LC.

Pulm Circ. 2019 Apr-Jun;9(2):2045894019859474. doi: 10.1177/2045894019859474.

4.

Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis.

Sofianopoulou E, Kaptoge S, Gräf S, Hadinnapola C, Treacy CM, Church C, Coghlan G, Gibbs JSR, Haimel M, Howard LS, Johnson M, Kiely DG, Lawrie A, Lordan J, MacKenzie Ross RV, Martin JM, Moledina S, Newnham M, Peacock AJ, Price LC, Rhodes CJ, Suntharalingam J, Swietlik EM, Toshner MR, Wharton J, Wilkins MR, Wort SJ, Pepke-Zaba J, Condliffe R, Corris PA, Di Angelantonio E, Provencher S, Morrell NW.

Eur Respir J. 2019 May 30;53(5). pii: 1801429. doi: 10.1183/13993003.01429-2018. Print 2019 May.

PMID:
30923185
5.

Tricuspid regurgitation and the right ventricle: risk stratification and timing of intervention.

Rana B, Robinson S, Francis R, Toshner M, Swaans MJ, Agarwal S, De Silva R, Rana AA, Nihoyannopoulos P.

Echo Res Pract. 2019 Feb 1. pii: ERP-18-0051.R1. doi: 10.1530/ERP-18-0051. [Epub ahead of print] Review.

6.

The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.

Newnham M, South K, Bleda M, Auger WR, Barberà JA, Bogaard H, Bunclark K, Cannon JE, Delcroix M, Hadinnapola C, Howard LS, Jenkins D, Mayer E, Ng C, Rhodes CJ, Screaton N, Sheares K, Simpson MA, Southwood M, Su L, Taboada D, Traylor M, Trembath RC, Villar SS, Wilkins MR, Wharton J, Gräf S, Pepke-Zaba J, Laffan M, Lane DA, Morrell NW, Toshner M.

Eur Respir J. 2019 Mar 28;53(3). pii: 1801805. doi: 10.1183/13993003.01805-2018. Print 2019 Mar.

7.

Myeloid angiogenic cells exhibit impaired migration, reduced expression of endothelial markers, and increased apoptosis in idiopathic pulmonary arterial hypertension 1.

Zhang Q, Zucco L, Toshner M, Morrell NW, Granton J, Stewart DJ, Kutryk MJB.

Can J Physiol Pharmacol. 2019 Apr;97(4):306-312. doi: 10.1139/cjpp-2018-0424. Epub 2018 Dec 17.

PMID:
30557040
8.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium.

Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5.

9.

Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension.

Swietlik EM, Ruggiero A, Fletcher AJ, Taboada D, Knightbridge E, Harlow L, Harvey I, Screaton N, Cannon JE, Sheares KKK, Ng C, Jenkins DP, Pepke-Zaba J, Toshner MR.

Eur Respir J. 2019 Jan 17;53(1). pii: 1801787. doi: 10.1183/13993003.01787-2018. Print 2019 Jan. No abstract available.

PMID:
30409818
10.

BMP9 Morphs into a Potential Player in Portopulmonary Hypertension.

Toshner M.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):819-821. doi: 10.1164/rccm.201810-1886ED. No abstract available.

11.

Increased Antielastase Activity in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.

Guo J, Lodge K, Newnham M, Bunclark K, Toshner M, Morrell NW, Li W.

Am J Respir Cell Mol Biol. 2018 Nov;59(5):652-655. doi: 10.1165/rcmb.2018-0060LE. No abstract available.

12.

Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension.

Bohnen MS, Ma L, Zhu N, Qi H, McClenaghan C, Gonzaga-Jauregui C, Dewey FE, Overton JD, Reid JG, Shuldiner AR, Baras A, Sampson KJ, Bleda M, Hadinnapola C, Haimel M, Bogaard HJ, Church C, Coghlan G, Corris PA, Eyries M, Gibbs JSR, Girerd B, Houweling AC, Humbert M, Guignabert C, Kiely DG, Lawrie A, MacKenzie Ross RV, Martin JM, Montani D, Peacock AJ, Pepke-Zaba J, Soubrier F, Suntharalingam J, Toshner M, Treacy CM, Trembath RC, Vonk Noordegraaf A, Wharton J, Wilkins MR, Wort SJ, Yates K, Gräf S, Morrell NW, Krishnan U, Rosenzweig EB, Shen Y, Nichols CG, Kass RS, Chung WK.

Circ Genom Precis Med. 2018 Oct;11(10):e002087. doi: 10.1161/CIRCGEN.118.002087.

13.

Hematopoietic stem cell transplantation alters susceptibility to pulmonary hypertension in Bmpr2-deficient mice.

Crosby A, Toshner MR, Southwood MR, Soon E, Dunmore BJ, Groves E, Moore S, Wright P, Ottersbach K, Bennett C, Guerrero J, Ghevaert C, Morrell NW.

Pulm Circ. 2018 Oct-Dec;8(4):2045894018801642. doi: 10.1177/2045894018801642. Epub 2018 Aug 30.

14.

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.

Gräf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, Hodgson J, Liu B, Salmon RM, Southwood M, Machado RD, Martin JM, Treacy CM, Yates K, Daugherty LC, Shamardina O, Whitehorn D, Holden S, Aldred M, Bogaard HJ, Church C, Coghlan G, Condliffe R, Corris PA, Danesino C, Eyries M, Gall H, Ghio S, Ghofrani HA, Gibbs JSR, Girerd B, Houweling AC, Howard L, Humbert M, Kiely DG, Kovacs G, MacKenzie Ross RV, Moledina S, Montani D, Newnham M, Olschewski A, Olschewski H, Peacock AJ, Pepke-Zaba J, Prokopenko I, Rhodes CJ, Scelsi L, Seeger W, Soubrier F, Stein DF, Suntharalingam J, Swietlik EM, Toshner MR, van Heel DA, Vonk Noordegraaf A, Waisfisz Q, Wharton J, Wort SJ, Ouwehand WH, Soranzo N, Lawrie A, Upton PD, Wilkins MR, Trembath RC, Morrell NW.

Nat Commun. 2018 Apr 12;9(1):1416. doi: 10.1038/s41467-018-03672-4.

15.

The outcome of reoperative pulmonary endarterectomy surgery.

Ali JM, Dunning J, Ng C, Tsui S, Cannon JE, Sheares KK, Taboada D, Toshner M, Screaton N, Pepke-Zaba J, Jenkins DP.

Interact Cardiovasc Thorac Surg. 2018 Jun 1;26(6):932-937. doi: 10.1093/icvts/ivx424.

PMID:
29373658
16.

The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade.

Bostock S, Sheares K, Cannon J, Taboada D, Pepke-Zaba J, Toshner M.

Eur Respir J. 2017 Dec 14;50(6). pii: 1701141. doi: 10.1183/13993003.01141-2017. Print 2017 Dec. No abstract available.

17.

Age should not be a barrier for pulmonary endarterectomy in carefully selected patients.

Newnham M, Hernández-Sánchez J, Dunning J, Ng C, Tsui S, Bunclark K, Sheares K, Taboada D, Toshner M, Pepke-Zaba J, Jenkins D, Cannon J.

Eur Respir J. 2017 Dec 7;50(6). pii: 1701804. doi: 10.1183/13993003.01804-2017. Print 2017 Dec. No abstract available.

18.

Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.

Hadinnapola C, Bleda M, Haimel M, Screaton N, Swift A, Dorfmüller P, Preston SD, Southwood M, Hernandez-Sanchez J, Martin J, Treacy C, Yates K, Bogaard H, Church C, Coghlan G, Condliffe R, Corris PA, Gibbs S, Girerd B, Holden S, Humbert M, Kiely DG, Lawrie A, Machado R, MacKenzie Ross R, Moledina S, Montani D, Newnham M, Peacock A, Pepke-Zaba J, Rayner-Matthews P, Shamardina O, Soubrier F, Southgate L, Suntharalingam J, Toshner M, Trembath R, Vonk Noordegraaf A, Wilkins MR, Wort SJ, Wharton J; NIHR BioResource–Rare Diseases Consortium; UK National Cohort Study of Idiopathic and Heritable PAH, Gräf S, Morrell NW.

Circulation. 2017 Nov 21;136(21):2022-2033. doi: 10.1161/CIRCULATIONAHA.117.028351. Epub 2017 Sep 28.

19.

Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.

Hernández-Sánchez J, Harlow L, Church C, Gaine S, Knightbridge E, Bunclark K, Gor D, Bedding A, Morrell N, Corris P, Toshner M.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217735820. doi: 10.1177/2045893217735820. Epub 2017 Sep 28.

PMID:
28956500
20.

The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension.

Price LC, Dimopoulos K, Marino P, Alonso-Gonzalez R, McCabe C, Kemnpy A, Swan L, Boutsikou M, Al Zahrani A, Coghlan GJ, Schreiber BE, Howard LS, Davies R, Toshner M, Pepke-Zaba J, Church AC, Peacock A, Corris PA, Lordan JL, Gaine S, Condliffe R, Kiely DG, Wort SJ.

Thorax. 2017 Nov;72(11):1035-1045. doi: 10.1136/thoraxjnl-2016-209725. Epub 2017 Sep 12. Review.

PMID:
28904006
21.

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.

Rhodes CJ, Ghataorhe P, Wharton J, Rue-Albrecht KC, Hadinnapola C, Watson G, Bleda M, Haimel M, Coghlan G, Corris PA, Howard LS, Kiely DG, Peacock AJ, Pepke-Zaba J, Toshner MR, Wort SJ, Gibbs JS, Lawrie A, Gräf S, Morrell NW, Wilkins MR.

Circulation. 2017 Jan 31;135(5):460-475. doi: 10.1161/CIRCULATIONAHA.116.024602. Epub 2016 Nov 21.

22.

Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension.

Aldabbous L, Abdul-Salam V, McKinnon T, Duluc L, Pepke-Zaba J, Southwood M, Ainscough AJ, Hadinnapola C, Wilkins MR, Toshner M, Wojciak-Stothard B.

Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2078-87. doi: 10.1161/ATVBAHA.116.307634. Epub 2016 Jul 28.

23.

HIF2α-arginase axis is essential for the development of pulmonary hypertension.

Cowburn AS, Crosby A, Macias D, Branco C, Colaço RD, Southwood M, Toshner M, Crotty Alexander LE, Morrell NW, Chilvers ER, Johnson RS.

Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8801-6. doi: 10.1073/pnas.1602978113. Epub 2016 Jul 18.

24.

Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.

Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, Treacy C, Ponnaberanam A, Condliffe R, Sheares K, Taboada D, Dunning J, Tsui S, Ng C, Gopalan D, Screaton N, Elliot C, Gibbs S, Howard L, Corris P, Lordan J, Johnson M, Peacock A, MacKenzie-Ross R, Schreiber B, Coghlan G, Dimopoulos K, Wort SJ, Gaine S, Moledina S, Jenkins DP, Pepke-Zaba J.

Circulation. 2016 May 3;133(18):1761-71. doi: 10.1161/CIRCULATIONAHA.115.019470. Epub 2016 Apr 6.

25.

The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities.

Millar FR, Summers C, Griffiths MJ, Toshner MR, Proudfoot AG.

Thorax. 2016 May;71(5):462-73. doi: 10.1136/thoraxjnl-2015-207461. Epub 2016 Mar 11. Review.

PMID:
26968969
26.

Genetic testing in pulmonary hypertension: how should our clinical practice reflect recent advances?

Toshner M.

Eur Respir J. 2016 Feb;47(2):388-9. doi: 10.1183/13993003.01858-2015. No abstract available.

27.

Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood.

Ormiston ML, Toshner MR, Kiskin FN, Huang CJ, Groves E, Morrell NW, Rana AA.

J Vis Exp. 2015 Dec 23;(106):e53384. doi: 10.3791/53384.

28.

Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis.

Crosby A, Soon E, Jones FM, Southwood MR, Haghighat L, Toshner MR, Raine T, Horan I, Yang P, Moore S, Ferrer E, Wright P, Ormiston ML, White RJ, Haight DA, Dunne DW, Morrell NW.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1355-65. doi: 10.1164/rccm.201412-2262OC.

29.

Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.

Soon E, Crosby A, Southwood M, Yang P, Tajsic T, Toshner M, Appleby S, Shanahan CM, Bloch KD, Pepke-Zaba J, Upton P, Morrell NW.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):859-72. doi: 10.1164/rccm.201408-1509OC.

30.

The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease.

Hadinnapola C, Li Q, Su L, Pepke-Zaba J, Toshner M.

Physiol Rep. 2015 Apr;3(4). pii: e12363. doi: 10.14814/phy2.12363.

31.

Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease.

Taboada D, Pepke-Zaba J, Jenkins DP, Berman M, Treacy CM, Cannon JE, Toshner M, Dunning JJ, Ng C, Tsui SS, Sheares KK.

Eur Respir J. 2014 Dec;44(6):1635-45. doi: 10.1183/09031936.00050114. Epub 2014 Sep 18.

32.

Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment.

Toshner M, Pepke-Zaba J.

F1000Prime Rep. 2014 Jun 2;6:38. doi: 10.12703/P6-38. eCollection 2014. Review.

33.

Transcript analysis reveals a specific HOX signature associated with positional identity of human endothelial cells.

Toshner M, Dunmore BJ, McKinney EF, Southwood M, Caruso P, Upton PD, Waters JP, Ormiston ML, Skepper JN, Nash G, Rana AA, Morrell NW.

PLoS One. 2014 Mar 20;9(3):e91334. doi: 10.1371/journal.pone.0091334. eCollection 2014.

34.

Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension.

Kuc RE, Carlebur M, Maguire JJ, Yang P, Long L, Toshner M, Morrell NW, Davenport AP.

Life Sci. 2014 Nov 24;118(2):391-6. doi: 10.1016/j.lfs.2014.02.020. Epub 2014 Feb 26.

35.

Reply to "Letter to the editor: 'Pulsatile pulmonary artery pressure: are fluid-filled catheters accurate in pulmonary hypertension?'".

Mackenzie Ross RV, Toshner MR, Soon E, Naeije R, Pepke-Zaba J.

Am J Physiol Heart Circ Physiol. 2013 Dec 1;305(11):H1682. doi: 10.1152/ajpheart.00763.2013. No abstract available.

36.

Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension.

MacKenzie Ross RV, Toshner MR, Soon E, Naeije R, Pepke-Zaba J.

Am J Physiol Heart Circ Physiol. 2013 Jul 15;305(2):H259-64. doi: 10.1152/ajpheart.00128.2013. Epub 2013 May 17.

37.

The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations.

Dunmore BJ, Drake KM, Upton PD, Toshner MR, Aldred MA, Morrell NW.

Hum Mol Genet. 2013 Sep 15;22(18):3667-79. doi: 10.1093/hmg/ddt216. Epub 2013 May 12.

38.

A practical and efficient cellular substrate for the generation of induced pluripotent stem cells from adults: blood-derived endothelial progenitor cells.

Geti I, Ormiston ML, Rouhani F, Toshner M, Movassagh M, Nichols J, Mansfield W, Southwood M, Bradley A, Rana AA, Vallier L, Morrell NW.

Stem Cells Transl Med. 2012 Dec;1(12):855-65. doi: 10.5966/sctm.2012-0093. Epub 2012 Nov 29.

39.

Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension.

Ormiston ML, Chang C, Long LL, Soon E, Jones D, Machado R, Treacy C, Toshner MR, Campbell K, Riding A, Southwood M, Pepke-Zaba J, Exley A, Trembath RC, Colucci F, Wills M, Trowsdale J, Morrell NW.

Circulation. 2012 Aug 28;126(9):1099-109. doi: 10.1161/CIRCULATIONAHA.112.110619. Epub 2012 Jul 25.

PMID:
22832786
40.

Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH.

Toshner M, Suntharalingam J, Fesler P, Soon E, Sheares KK, Jenkins D, White P, Morrell NW, Naeije R, Pepke-Zaba J.

Eur Respir J. 2012 Sep;40(3):612-7. doi: 10.1183/09031936.00134111. Epub 2012 Feb 23.

41.

The fibrocyte in pulmonary hypertension: we seek him here, we seek him there.

Toshner MR, Morrell NW.

Eur Respir J. 2012 Jan;39(1):5-6. doi: 10.1183/09031936.00127111. No abstract available.

42.

Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension.

Soon E, Doughty NJ, Treacy CM, Ross RM, Toshner M, Upton PD, Sheares K, Morrell NW, Pepke-Zaba J.

Pulm Circ. 2011 Apr-Jun;1(2):244-9. doi: 10.4103/2045-8932.83450.

43.

Risk of potentially life-threatening thyroid dysfunction due to amiodarone in idiopathic pulmonary arterial hypertension patients.

Soon E, Toshner M, Mela M, Grace A, Sheares K, Morrell N, Pepke-Zaba J.

J Am Coll Cardiol. 2011 Feb 22;57(8):997-8. doi: 10.1016/j.jacc.2010.09.059. No abstract available.

44.

Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension.

Soon E, Treacy CM, Toshner MR, MacKenzie-Ross R, Manglam V, Busbridge M, Sinclair-McGarvie M, Arnold J, Sheares KK, Morrell NW, Pepke-Zaba J.

Thorax. 2011 Apr;66(4):326-32. doi: 10.1136/thx.2010.147272. Epub 2011 Feb 5.

PMID:
21297151
45.

Endothelial progenitor cells in pulmonary hypertension - dawn of cell-based therapy?

Toshner M, Morrell NW.

Int J Clin Pract Suppl. 2010 Jan;(165):7-12. doi: 10.1111/j.1742-1241.2009.02232.x. Review.

PMID:
19958395
46.

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S.

Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7. doi: 10.1164/rccm.201001-0123OC. Epub 2010 Jun 25.

47.

Pulmonary hypertension: advances in pathogenesis and treatment.

Toshner M, Tajsic T, Morrell NW.

Br Med Bull. 2010;94:21-32. doi: 10.1093/bmb/ldq012. Epub 2010 May 6. Review.

PMID:
20447940
48.

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.

Toshner MR, Gopalan D, Suntharalingam J, Treacy C, Soon E, Sheares KK, Morrell NW, Screaton N, Pepke-Zaba J.

J Heart Lung Transplant. 2010 Jun;29(6):610-5. doi: 10.1016/j.healun.2009.12.014. Epub 2010 Mar 15.

49.

Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension.

Toshner M, Voswinckel R, Southwood M, Al-Lamki R, Howard LS, Marchesan D, Yang J, Suntharalingam J, Soon E, Exley A, Stewart S, Hecker M, Zhu Z, Gehling U, Seeger W, Pepke-Zaba J, Morrell NW.

Am J Respir Crit Care Med. 2009 Oct 15;180(8):780-7. doi: 10.1164/rccm.200810-1662OC. Epub 2009 Jul 23.

50.

NT-proBNP does not rise on acute ascent to high altitude.

Toshner MR, Thompson AA, Irving JB, Baillie JK, Morton JJ, Peacock AJ.

High Alt Med Biol. 2008 Winter;9(4):307-10. doi: 10.1089/ham.2008.1054.

PMID:
19115915

Supplemental Content

Loading ...
Support Center